{'fraction_non_alphanumeric': 0.02715466351829988, 'fraction_numerical': 0.025974025974025976, 'mean_word_length': 5.281481481481482, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MP17-13 DEVELOPMENT OF A HIGH CONTENT DRUG SCREENING PLATFORM FOR BLADDER CANCER ORGANOIDS

inhibitor treatment. Our approach identified Forkhead Box A1 (FOXA1) as a shared potential MR in UMUC1 and SW780. CRISPR/Cas9 KO of FOXA1 in UMUC1 revealed PPARɣ-regulated genes within the FOXA1 regulon, including T Box 3 (TBX3), Epithelial Membrane Protein 3 (EMP3) and Breast Carcinoma Amplified Sequence 1 (BCAS1) are no longer regulated following FOXA1 KO. CONCLUSIONS: Oncogenic and tumor suppressive functions have been attributed to PPARɣ. We have identified a network of potential PPARɣ-responsive MRs that function in human BC in a contextdependent manner. Among these, loss of function experiments definitively identify FOXA1 as one such MR. Future work will determine how differential PPARɣ regulon activity contributes to disease pathogenesis.